Poplar-type Propolis Dry Extract ESIT12 : Immunomodulation Efficacy Study

Last updated: September 23, 2024
Sponsor: Fytexia
Overall Status: Completed

Phase

N/A

Condition

Respiratory Syncytial Virus (Rsv) Infection

Treatment

Placebo

Verum

Clinical Study ID

NCT05598749
ESIT12IES
  • Ages 25-69
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The aim of the present investigation is to evaluate the immunomodulation effect of ESIT12, a poplar-type propolis dry extract standardized in polyphenols, and its efficacy in subjects at risk of contracting upper respiratory tract infections (URTIs), during a 12-week supplementation period plus 4-week follow-up.

The number of onset of upper respiratory tract infections, the symptoms severity and lasting and interferences with well-being will be assessed with WURSS-24 questionnaire. The quality of life will be assessed with the SF-36 questionnaire and a testimonial. Blood immune markers will also be assessed. Finally, long lasting benefits will additionally be evaluated 4 weeks after end of the supplementation period. The design of the study is double-blind, randomized, parallel and placebo controlled.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • inactive or minimally active according to the IPAQ short form questionnaire

  • BMI 18,5-29,9

Exclusion

Exclusion Criteria:

  • Pregnant women, breastfeeding women, women positive at Beta-HCG serology test andwho hope to become pregnant

  • Allergy to beehive products and known allergy (general)

  • Cystic fibrosis

  • Congenital or acquired immunodeficiency syndrome and disease

  • History of asthma (within prior 24 months) or chronic respiratory disease

  • Subjects who underwent medical treatment for COVID-19 within last 3 months

  • History of immune system disorder or auto-immune disorder

  • History of treated diabetes or treated hypertension

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal,cardiovascular, hepatic, neurologic diseases, and malignancies

  • Cancers

  • Those considered unsuitable for the participation by the physician

  • No vaccination within 12 weeks prior to enrolling in the study

  • No antibiotics within 12 weeks prior to enrolling in the study

  • No anti-inflammatory drugs within 4 weeks prior to enrolling in the study

  • No steroids within 12 weeks prior to enrolling in the study

  • No immunological drugs within 4 weeks prior to enrolling in the study

  • No food/dietary supplements within 4 weeks prior to enrolling in the study

  • No current or recent participation in another clinical trial (within 30 days priorto screening)

Study Design

Total Participants: 309
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
December 05, 2022
Estimated Completion Date:
July 03, 2024

Connect with a study center

  • UCAM (Universidad Catolica San Antonio de Murcia)

    Murcia,
    Spain

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.